Financial Performance - Revenue for Q1 2024 was $18.4 million, a decrease of 14% compared to $21.4 million in Q1 2023[5] - Gross margin for Q1 2024 was reported at 46%, while non-GAAP adjusted gross margin was 57%, consistent with Q1 2023[6] - Operating expenses for Q1 2024 were $30.0 million, with non-GAAP operating expenses at $25.6 million, compared to $29.7 million in Q1 2023[6] - Loss from operations for Q1 2024 was $21.6 million, while non-GAAP loss from operations was $15.2 million[11] - Loss from operations for Q1 2024 was $21,585,000, compared to $17,436,000 in Q1 2023, indicating an increase in losses[22] - Non-GAAP loss from operations improved to $15,172,000 in Q1 2024 from $17,436,000 in Q1 2023[22] - The company incurred $2,045,000 in provisions for excess and obsolete inventories due to product discontinuation and lease exit inventory charges[22] - An impairment charge of $2,971,000 was recorded in Q1 2024[22] - Restructuring costs amounted to $1,397,000 in the first quarter of 2024[22] Operational Highlights - The installed base of instruments increased by 22% year-over-year, reaching 1,213 units as of March 31, 2024[11] - Total publications citing Akoya's technology rose to 1,307, marking a 52% increase from the previous year[11] - Akoya established a new Manufacturing Center of Excellence to scale internal reagent manufacturing[5] - The KR-HT5 instrument received premarket approval from China's National Medical Products Administration[5] Future Outlook - The company expects full-year 2024 revenue to be in the range of $104.0 million to $112.0 million[7] - Cash, cash equivalents, and marketable securities totaled $61.6 million as of March 31, 2024[11]

MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement today under which the parties will develop market opportunities for combining Akoya's PhenoImager HT platform and NeraCare's Immunoprint assay for patient stratification and therapy selection in early-stage melanoma patients. Melanoma is th ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Akoya Biosciences (AKYA) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 13, 2024, might help the stock move higher if these key numbers are better than e ...

MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company's PhenoCycler®-Fusion and the PhenoImager® HT platforms. "Spatial biology is transforming drug discovery, translational sciences, and clinical research, and advancing our ability to u ...

MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and ...

MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of its PhenoCode™ Signature Panels and preliminary data from the T ...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that it has been named as a qualified contract research organization (CRO) of Akoya Biosciences (Nasdaq: AKYA; “Akoya”). By combining Akoya's single-cell imaging solutions with BostonGene's unparalleled expertise in spatial proteomics sample processing and analysis, researchers will gain unprecedented access to the intricate landscape of cellular biology, paving the way for ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Subbu Nambi - Guggenheim Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley John Sourbeer - UBS Mark Massaro - BTIG Rachel Vatnsdal - JP Morgan Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Fourth Quarter 2023 Earnings Conference Call. At this time, all participant ...

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.52%. A quarter ago, it was expected that this tissue analysis provider would post a loss of $0.37 per share when it actually produced a loss of $0.26, delivering a surprise of 29.73%.Over the last four quarters, the c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaw ...